Santaris Pharma enters alliance with Britain's Shire  

2009.08.27
Danish biotech firm Santaris Pharma has entered a research alliance with the British pharmaceutical company Shire to develop new medicines for the treatment of rare genetic disorders
Danish biotech firm Santaris Pharma has entered a research alliance with the British pharmaceutical company Shire to develop new medicines for the treatment of rare genetic disorders based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, reports financial daily newspaper Børsen.
 
Santaris Pharma will receive initial early stage payments of USD 6.5m (DKK 34m) for technology access, exclusivity for three pre-defined targets and initial discovery funding, and an additional early stage payment of USD 13.5m (DKK 70m) upon successful completion of certain initial studies, the company writes in a press release.
 
Søren Tulstrup, president and CEO of Santaris Pharma says: "We are delighted that the increasing interest in the LNA Drug Platform and our Drug Discovery Engine so quickly has materialised in our fourth strategic alliance. This alliance with Shire demonstrates the broad utility of Santaris Pharma's proprietary LNA Drug Platform for developing treatments for an extensive range of diseases, now also including rare genetic disorders."
 
Founded in 2003, Santaris Pharma is based in Hørsholm to the north of Copenhagen, and employs a staff of around 65 people. The company's pharmaceutical partners are Enzon Pharmaceuticals, GlaxoSmithKline and Wyeth Pharmaceuticals.
 
Link > Santaris Pharma        

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×